Combination of Oral Anticoagulant with Antiplatelet and All-cause Mortality in Elderly Patients with Atrial Fibrillation and Ischemic Heart Disease

Shijun Li1*, Li Zhang1, Yangyu Wang1, Na Li1 and Hongjie Li1

1Department of Geriatric Cardiology, Chinese PLA General Hospital at No. 28, Fuxing Road, Beijing 100853, PR China.

ABSTRACT

Aim: Clinicians are often face the dilemma of choosing more appropriate antithrombotic regimen, since there is no evidence regarding the role of combination of Oral Anticoagulant (OAC) and antiplatelet which played in elderly patients with Atrial Fibrillation (AF) and Ischemic Heart Disease (IHD). We therefore aimed to investigate the effect of combination of OAC and antiplatelet on all-cause mortality in elderly patients with AF and IHD.

Methods: A total of 669 elderly patients with AF and IHD between 2008 and 2014 were included in this study.

Results: During a median follow-up of 1.3 years, the mortality rate was 74.3% for patients with...
antiplatelets, 58.6% for OAC and 42.9% for combination of both, respectively. OAC and/or antiplatelet use were associated with risk of mortality (chi-square=11.03, log rank p = 0.004) using unadjusted Kaplan-Meier analysis. In overall cohort, the adjusted hazard ratios for mortality for combination of OAC and antiplatelet was 0.41 (95% CI 0.19-0.87, p = 0.019) as compared to antiplatelet use, 0.80 (95% CI 0.39-1.64, p = 0.541) as compared to OAC use. In subgroup age ≥ 75 years, the adjusted hazard ratios for mortality were 0.40 (95% CI 0.16-1.02, p = 0.054) for combination of OAC and antiplatelet as compared to antiplatelet use, 0.79 (95% CI 0.31-1.96, p = 0.605) for combination of OAC and antiplatelet as compared to OAC use, and compared to antiplatelet use, the adjusted hazard ratio for mortality were 0.51 (95% CI 0.32-0.81, p = 0.005) for OAC use.

**Conclusions:** Combination of OAC with antiplatelet is associated with reduced all-cause mortality and OAC is better on outcome as compared to antiplatelet agents, but OAC plus antiplatelet is not superior to OAC in elderly patients with AF and IHD and in subgroup aged ≥ 75 years.

**Keywords:** Antiplatelet; anticoagulant; elderly; atrial fibrillation; ischemic heart disease.

### 1. INTRODUCTION

Atrial Fibrillation (AF) and Ischemic Heart Disease (IHD) are prevalent with increasing age, particularly among those older than age 60 [1]. Previous evidence showed that Oral Anticoagulant (OAC) is superior to antiplatelets for stroke protection in AF [2], and OAC is more effective than antiplatelet drugs in reducing the risk of thromboembolic events associated with AF [3]. Antiplatelet agents are preferred in patients with IHD as well as those receiving percutaneous coronary intervention (PCI) [4-6]. However, clinicians are often face the dilemma of choosing more appropriate antithrombotic regimen for elderly patients with both AF and IHD. The PIONEER AF-PCI study is the first randomized comparison of VKA vs novel oral anticoagulant therapy in patients with NVAF receiving antiplatelet therapy after PCI to assess the relative risks of bleeding complications in patients at least 18 years of age who have AF and have undergone a PCI procedure [7]. There is no evidence regarding the role of combination of OAC and antiplatelet which played in elderly patients with AF and IHD. We therefore investigated the effect of combination of OAC and antiplatelet on all-cause mortality in elderly patients with AF and IHD.

### 2. PATIENTS AND METHODS

#### 2.1 Study Design

This was a retrospective analytical study.

#### 2.2 Setting

The study conducted in Chinese PLA General Hospital, Beijing, China.

#### 2.3 Study Population

Selected patients' data available for the period between 2008 and 2014 were included in this study. A total of 699 older patients (≥ 60 years) with AF and IHD were eligible for this study. Diagnosis of AF is based on electrocardiography (ECG) (12-lead ECG), or 24-hour Holter ECG, and medical history at enrolment. IHD included myocardial infarction, unstable and stable angina, which was diagnosed according to recent cardiovascular guideline. Demographics, other medical diagnoses, OAC or antiplatelet agents, and laboratory data were also collected from the patients discharged. Exclusion criteria included any one of the following conditions: rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, mitral valve repair, and death in hospital. CHADS\textsubscript{2} score (cardiac failure or dysfunction, hypertension, age ≥75 years, diabetes, stroke/transient ischemic attack (doubled) was used for stroke risk stratification.

#### 2.4 Antithrombotic Treatment Regimens

We defined the following antithrombotic treatment regimens: single-antiplatelet therapy (aspirin and/or clopidogrel), single-anticoagulant therapy (warfarin, dabigatran or rivaroxaban), antiplatelet plus anticoagulant therapy (antiplatelet agents and anticoagulants). A dosing regimen was used for aspirin (100 mg/d), clopidogrel (75 mg/d), rivaroxaban (10 mg/d) and dabigatran (110 mg, 2/d). Warfarin dose was allowed to change on the basis of international ratio (INR) level.

#### 2.5 Outcome Measure

The outcome measure was all-cause mortality. Survival status was ascertained on 31 December
2014 from an electronic clinical information system in our hospital.

2.6 Ethical Considerations

The registry and analysis of data were approved by ethics committee of our hospital. Individual patient consent was not required, but patients or his/her relatives were informed of entry into our study.

2.7 Statistical Analysis

For baseline characteristics, categorical variables are presented as frequencies with percentages and continuous variables as means with SDs. All continuous variables were first tested for normality and homogeneity of variance. The continuous variables with normal distribution were analysed using student’s t-tests and Mann-Whitney U rank-sum tests were used for these continuous variables with non-normality. Pearson chi-square tests for categorical variables were used to calculate and test hazard ratios. Differences were considered statistically significant at p < 0.05. Statistical analyses were performed with IBM SPSS Statistic 21.0 (IBM Corporation, Armonk, NY, USA).

3. RESULTS

3.1 Patient Characteristics

A total of 699 patients were included in the present analysis. Among these patients, 31 patients had paroxysmal AF, 668 patients had persistent or permanent AF. 42.9% patients received aspirin, 48.1% patients prescribed OACs (warfarin or novel oral anticoagulants), 9.0% patients took antiplatelet and OACs. In patients aged ≥75 years, 46.5% patients received antiplatelets, 45.5% patients prescribed OACs, 8.0% patients took antiplatelets and OACs. The mean CHADS2 scores were 3.84 in patients receiving antiplatelets, 3.88 in patients receiving OACs and 4.22 in patients receiving both antiplatelet and OAC, respectively. Baseline demographics of these patients are listed in Table 1. During a median follow-up of 1.3 years [interquartile range (IQR): 0.5-2.3 years], mortality rate gradually decreased in taking antiplatelets (74.3%), OACs (58.6%) and both combination (42.9%) patients (Table 1).

3.2 Outcomes in Relation to OAC and /or Antiplatelet Use

In the unadjusted analysis, OAC and /or antiplatelet use was associated with risk of mortality (chi-square=11.03, log rank p = 0.004), and OAC or combination of OAC and antiplatelets was associated with reduced mortality as compared with antiplatelet using Kaplan-Meier analysis (Fig. 1).

Compared to antiplatelet use, the adjusted hazard ratio for mortality were 0.51 (95% CI 0.32-0.81, p = 0.005) for OAC use, 0.41 (95% CI 0.19-0.87, p = 0.019) for combination of antiplatelet and OAC. Compared to OAC use, the adjusted hazard ratios for mortality were 1.96 (95% CI 1.23-3.11, p = 0.005) for antiplatelet use, 0.80 (95% CI 0.39-1.64, p = 0.541) for combination of OAC and antiplatelet (Table 2, Fig. 2).

In subgroup analysis, as compared to antiplatelet use, the adjusted hazard ratios for mortality were 0.51 (95% CI 0.30-0.86, p = 0.012) for OAC use, 0.40 (95% CI 0.16-1.02, p = 0.054) for combination of OACs and antiplatelets in subgroup age ≥ 75 years (Table 3). In addition, as compared to OAC use, the adjusted hazard ratios for mortality were 0.50 (95% CI 1.16-3.38, p = 0.0012) for antiplatelet use, 0.79 (95% CI 0.31-1.96, p = 0.605) for combination of OAC and antiplatelet in subgroup age ≥ 75 years (Table 3).

4. DISCUSSION

In this study, we report an association of combination of OAC and antiplatelet with all-cause mortality in elderly patients with AF and IHD. We show that combination of OAC and antiplatelet is associated with reduced all-cause mortality and OAC are better on outcome as compared to antiplatelet, but OAC plus antiplatelet is not superior to OAC in elderly patients with AF and IHD and in subgroup aged ≥ 75 years.

Clinicians often meet a dilemma for antithrombotic therapy, where risk of stroke or stent thrombosis must be balanced with bleeding risk in elderly patients with AF and IHD. As we known, the cornerstone of AF treatment should include OACs if 1 or more stroke risk factors (such as vascular disease) are present [8], whereas initial preventive treatment after myocardial infarction or PCI consists of drugs for platelet antiaggregation [9]. Both single-
Table 1. Baseline characteristics based on OAC and/or antiplatelet use

| Characteristics          | Single-antiplatelets (n=300) | Single-anticoagulants (n=336) | Both combination (n=63) | p value |
|--------------------------|-------------------------------|-------------------------------|-------------------------|---------|
| Age, years               | 83.51±6.30                   | 79.33±6.35                   | 77.78±6.68              | < 0.001 |
| Age ≥ 75 years, %        | 269(89.7)                    | 263(78.3)                    | 46(73.0)                | < 0.001 |
| Male sex, %              | 179(59.7)                    | 247(73.5)                    | 45(71.4)                | 0.001   |
| BMI, kg/m²               | 25.28±4.07                   | 26.34±4.58                   | 26.14±5.09              | 0.112   |
| Smoker, %                | 164(54.8)                    | 182(54.1)                    | 33(52.1)                | 0.942   |
| Heart rate, bpm          | 74.97±16.80                  | 74.87±14.31                  | 75.18±21.76             | 0.990   |
| SBP, mmHg                | 128.32±22.15                 | 124.75±19.32                 | 125.37±21.83            | 0.092   |
| DBP, mmHg                | 72.14±12.88                  | 71.77±11.39                  | 72.40±12.23             | 0.895   |
| CHADS₂ score             | 3.84±1.32                    | 3.88±1.37                    | 4.22±1.34               | 0.012   |

Medical histories

| Hypertension, %          | 172(57.2)                    | 179(53.4)                    | 39(62.3)                | 0.362   |
| Diabetes, %              | 87(29.1)                     | 125(37.2)                    | 24(38.1)                | 0.074   |
| CHF, %                   | 288(96.0)                    | 331(98.5)                    | 62(98.4)                | 0.119   |
| Stroke, %                | 170(56.7)                    | 206(61.3)                    | 48(76.2)                | 0.015   |
| Lung disease, %          | 49(16.3)                     | 88(26.2)                     | 9(14.8)                 | 0.005   |
| Value disease, %         | 67(22.4)                     | 101(30.0)                    | 10(16.4)                | 0.028   |
| Pacemaker, %             | 24(8.1)                      | 28(8.2)                      | 7(11.1)                 | 0.714   |
| PCI or CABG, %           | 108(36.1)                    | 165(49.2)                    | 51(80.6)                | < 0.001 |

Laboratory tests

| Creatinine, µmol/L       | 130.18±66.45                 | 118.61±44.10                 | 114.59±37.69            | 0.012   |
| eGFR, ml/min             | 46.32±18.19                  | 52.52±18.68                  | 54.10±18.87             | < 0.001 |
| Haemoglobin, g/L         | 127.18±15.68                 | 131.22±16.56                 | 128.90±15.55            | 0.007   |

Medications

| ACEIs, %                 | 49(16.4)                     | 92(27.4)                     | 12(19.7)                | 0.004   |
| ARBs, %                  | 161(53.8)                    | 193(57.3)                    | 46(73.0)                | 0.020   |
| Beta-blockers, %         | 247(82.2)                    | 293(87.2)                    | 56(88.9)                | 0.149   |
| Digoxin, %               | 76(25.3)                     | 101(30.1)                    | 17(27.0)                | 0.409   |
| Statins, %               | 98(32.7)                     | 174(51.8)                    | 49(77.8)                | < 0.001 |
| Nitrates, %              | 125(41.7)                    | 103(30.8)                    | 20(32.3)                | 0.016   |

Endpoint event

| All-cause death, %       | 223(74.3)                    | 197(58.6)                    | 27(42.9)                | < 0.001 |

Notes: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHF, cardiac heart failure; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CHADS₂, cardiac failure or dysfunction, hypertension, age ≥ 75 years, diabetes, stroke or transient ischemic attack [doubled].

Dual-antiplatelet therapy are valuable after an MI and after a PCI procedure [10,11]. Benefit of long-term OAC therapy in selected patients with AF is also demonstrated by a randomized trial [2]. Use of clopidogrel without aspirin was associated with a significant reduction in bleeding complications and no increase in the rate of thrombotic events in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention [12]. The WOEST (What Is the Optimal Antiplatelet and Anticoagulant Therapy in Patients with Oral Anticoagulation and Coronary Stenting) study showed that a composite secondary end point of death, myocardial infarction and stent thrombosis was significantly lower in the dual-therapy group compared with the triple-therapy group [12]. Oral anticoagulant plus aspirin were associated with a significant increased risk of all-cause death, and OAC and clopidogrel was equal or better on both benefit and safety outcomes compared to triple therapy in AF patients after myocardial infarction and PCI [13]. Addition of antiplatelet to OAC is not associated with a reduction in risk of recurrent coronary events or thromboembolism, whereas risk of bleeding is increased significantly in atrial fibrillation patients with stable coronary artery disease [14]. However, the evidence for an
optimal long-term antithrombotic treatment strategy in elderly patients with AF coexisting IHD is little. As we known, only one study demonstrated that among older patients aged ≥65 years with AF and IHD, antithrombotic strategy was not associated with improved 1-year adjusted outcomes [15]. Therefore, further investigation into optimizing antithrombotic strategies in this population is warranted. In our study, only 9.0% patients received the combination of antiplatelet and OAC, and the mean CHADS\textsubscript{2} scores were 4.22 in patients with both antiplatelet and OAC. We showed that combination of OAC and antiplatelet was associated with reduced all-cause mortality as compared with antiplatelets, however the antithrombotic combination was not superior to OAC in elderly patients with AF and IHD, and OAC use was better on outcome as compared with antiplatelets.

Prior findings of an annual stroke risk of 23.5% in patients with AF 80 to 89 years old [16], however, bleeding with warfarin is more common in the first year of treatment in very old patients with [17], and older patients are at higher risk for bleeding after falls, physicians may favour platelet inhibitors over oral anticoagulation in older patients due to a perceived lower bleeding risk [18], although data from clinical trials show similar bleeding rates for aspirin plus clopidogrel versus warfarin alone [19]. Our study showed that among older patients with AF and IHD, OAC use was low, and only 8.0% patients took antiplatelet plus OAC in subgroup aged ≥75 years. Moreover, the optimal antithrombotic

![Table 2. Cox regression analyses for the association of OAC and/or antiplatelet use with mortality in elderly patients with AF and IHD](image)

| OAC and/or antiplatelet therapy | Univariable hazard ratio [95% CI] | p value | Multivariable hazard ratio [95% CI] | p value |
|---------------------------------|----------------------------------|---------|-----------------------------------|---------|
| Single-antiplatelets Reference  | Reference                        | 0.004   | Reference                         | 0.007   |
| Single-OACs 0.79(0.65-0.96)     | 0.017                            | 0.51(0.32-0.81) | 0.005 |
| Both combination 0.57(0.38-0.84)| 0.005                            | 0.41(0.19-0.87) | 0.019 |
| Single-antiplatelets 1.27(1.04-1.53)| 0.017                      | 1.96(1.23-3.11) | 0.005 |
| Single-OACs Reference          | Reference                        |         | Reference                         |         |
| Both combination 0.72(0.48-1.07)| 0.100                            | 0.80(0.39-1.64) | 0.541 |

Adjusting for age, gender, BMI, smoker, heart rate, SBP, DBP, CHADS\textsubscript{2}, lung disease, valve disease, pacemaker, PCI or CABG, eGFR, hemoglobin, ACEIs, ARBs, beta-blockers, digoxin, statins, nitrates.

Table 3. Cox regression analyses for the association of OAC and/or antiplatelet therapy with mortality in subgroups aged ≥75 and < 75 years

| OAC and/or antiplatelet therapy | Univariable hazard ratio [95% CI] | p value | Multivariable hazard ratio [95% CI] | p value |
|---------------------------------|----------------------------------|---------|-----------------------------------|---------|
| In patients aged <75 years      |                                  |         |                                    |         |
| Single-antiplatelets Reference  | Reference                        | 0.041   | Reference                         | 0.007   |
| Single-OAC 0.45(0.44-0.92)      | 0.030                            | 0.25(0.09-0.37) | 0.002 |
| Both combination 0.30(0.12-0.76)| 0.001                            | 0.38(0.11-0.63) | 0.021 |
| Single-antiplatelets 1.32(1.04-1.66)| 0.030                      | 2.08(1.68-2.59) | 0.002 |
| Single-OACs Reference           | Reference                        |         | Reference                         |         |
| Both combination 0.40(0.16-0.97)| 0.042                            | 1.43(0.20-2.36) | 0.725 |
| In patients aged ≥75 years      |                                  |         |                                    |         |
| Single-antiplatelets Reference  | Reference                        | 0.085   | Reference                         | 0.022   |
| Single-OACs 0.83(0.67-1.02)     | 0.079                            | 0.51(0.30-0.86) | 0.012 |
| Both combination 0.67(0.42-1.07)| 0.093                            | 0.40(0.16-1.02) | 0.054 |
| Single-antiplatelets 1.21(0.98-1.49)| 0.079                      | 1.98(1.16-3.38) | 0.012 |
| Single-OACs Reference           | Reference                        |         | Reference                         |         |
| Both combination 0.81(0.50-1.30)| 0.373                            | 0.79(0.31-1.96) | 0.605 |

Adjusting for age, gender, BMI, smoker, heart rate, SBP, DBP, CHADS\textsubscript{2}, lung disease, valve disease, pacemaker, PCI or CABG, eGFR, hemoglobin, ACEIs, ARBs, beta-blockers, digoxin, statins, nitrates.
strategy in patients with AF and IHD remains unresolved. Some evidence demonstrated that the absolute benefit of warfarin in thromboembolic protection also increased with age [20,21]. Octogenarian AF patients undergoing PCI/stenting have a high mortality rate and major adverse cardiac events (death, acute myocardial infarction and/or revascularisation of target lesion), which can be reduced by OAC therapy [22]. Our study showed that OAC plus antiplatelet wasn’t superior to OAC or aspirin for outcome in subgroup aged ≥ 75 years; but OAC was better on outcome as compared to antiplatelets. The results suggested that OACs should be the optimal antithrombotic strategy for long-term outcome in elderly patients aged ≥ 75 years with AF and IHD.
Fig. 2. Forest plots of hazard ratios (95\% CIs) for mortality in antiplatelet and/or anticoagulant therapy

Notes: multivariables included age, gender, BMI, smoker, heart rate, SBP, DBP, CHADS₂, lung disease, valve disease, pace maker, PCI or CABG, eGFR, hemoglobin, ACEIs, ARBs, beta-blockers, digoxin, statins, nitrates.

Our study has some limitations. In elderly patients with AF and IHD, we investigated the relationships between anticoagulant and/or antiplatelet and all-cause mortality; however we didn’t further observed the prognostic significance of triple antithrombotic therapy (OAC plus dual antiplatelet therapy). Patients without medication records were excluded, and a proxy for discharge medications was used. We also lacked data regarding both bleeding events, which precluded a net clinical benefit analysis, and AF and treatment duration; medication changes could have confounded our results. There were significantly statistical differences of some variables such as statin usage, eGFR, etc. among the three groups, so multivariate Cox regression was used to balance the effects of the confounders on outcome. Finally, the time point when AF was defined at enrollment, so we were unable to differentiate between persistent and permanent AF.

5. CONCLUSIONS

Combination of OAC with antiplatelet is associated with reduced all-cause mortality and OAC is better on outcome as compared to antiplatelets, but OAC plus antiplatelet is not superior to OAC in elderly patients with AF and IHD and in subgroup aged ≥ 75 years.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297-305. [PubMed: 19721017].
2. ACTIVE Writing Group of the ACTIVE Investigators, Connolly SJ, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): A randomised controlled trial. Lancet. 2006;367(9526):1903-1912. [PubMed: 16765759].
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. [PubMed: 17577005].
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(20):494-502. [PubMed: 11519503].

5. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershkovich AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knutti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van ’t Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20):2569-2619. [PubMed: 22922416].

6. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DC, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study investigators. N Engl J Med. 1998; 339(23):1665-1671. [PubMed: 9834303].

7. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169(4):472-478. [PubMed: 25819853].

8. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385–1413. [PubMed: 22923145].

9. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar TG, Anderson JL. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;126(7):875–910. [PubMed: 22800849].

10. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither: The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316(141):1337–1343. [PubMed: 9563981].

11. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S. Clopidogrel in unstable angina to prevent recurrent ischemic events trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation. 2004;110(10):1202–1208. [PubMed: 15313956].

12. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijssen JG, van ’t Hof AW, ten Berg JM. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-1115. [PubMed: 23415013].

13. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Køber L, Torp-Pedersen C, Hansen ML. Oral anticoagulation and antiplatelets in...
atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62(11):981-989. [PubMed: 23747760].

14. Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, Sørensen R, Køber L, Torp-Pedersen C, Hansen ML. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: A nationwide cohort study. Circulation. 2014;129(15):1577-1585. [PubMed: 24470482].

15. Hess CN, Broderick S, Piccini JP, Alexander KP, Newby LK, Shaw LK, Mahaffey KW, Alexander JH, Peterson ED, Granger CB, Lopes RD. Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. Am Heart J. 2012;164(4):607-615. [PubMed: 23067921].

16. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke. 1991;22(8):983–988. [PubMed: 1866765].

17. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689-2696. [PubMed: 17515465].

18. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: Physicians' fears often unfounded. Arch Intern Med. 2003;163(13):1580–1586. [PubMed PMID: 12860581].

19. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anti-coagulation restenosis study investigators. N Engl J Med. 1998;339(23):1665-1671. [PubMed PMID: 9834303].

20. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. [PubMed PMID: 17577005].

21. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knotnerus JA, Boode B, Ezekowitz MD, Singer DE. Effect of age on stroke prevention therapy in patients with atrial fibrillation: The atrial fibrillation investigators. Stroke. 2009;40(4):1410-1416. [PubMed PMID: 19182090].

22. Caballero L, Ruiz-Nodar JM, Marín F, Roldán V, Hurtado JA, Valencia J, Manzano-Fernandez S, Sogorb F, Valdes M, Lip GY. Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting. Age Ageing. 2013;42(1):70-75. [PubMed PMID: 22983982].